Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
System-wide comp sales for all clinics open 13 months or more are expected to be in the mid-single digits in 2024. New franc...
Joint (NASDAQ:JYNT) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.02) by 20...
B. Riley Securities analyst Jeff Van Sinderen maintains Joint (NASDAQ:JYNT) with a Buy and raises the price target from $12 ...
Roth MKM analyst George Kelly reiterates Joint (NASDAQ:JYNT) with a Buy and raises the price target from $13 to $16.
Joint (NASDAQ:JYNT) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.01) by 700 ...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dipping around 0.5% on Friday. The Dow traded up...
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quart...
